




Docket No.: A0848.70010US00  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Silence  
Serial No.: 10/541,708  
Confirmation No.: 6032  
Filed: July 8, 2005  
For: THERAPEUTIC POLYPEPTIDES, HOMOLOGUES THEREOF,  
FRAGMENTS THEREOF AND FOR USE IN MODULATING  
PLATELET-MEDIATED AGGREGATION  
Examiner: Szperka, Michael Edward  
Art Unit: 1644

<b>Certificate of Mailing Under 37 CFR 1.8(a)</b>	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>October 17, 2007</u>	 Sylvia Householder

**RESPONSE TO RESTRICTION AND SPECIES ELECTION REQUIREMENTS**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the restriction requirement mailed September 17, 2007, Applicant hereby elects Group I – Claims 1-12, 14, 15 and 22, drawn to polypeptides and compositions comprising single domain antibodies.

In response to the species election requirement set forth on pages 3-4 of the paper mailed September 17, 2007, Applicant elects as the first antigen, von Willebrand Factor (vWF), and as the second antigen, serum albumin, with traverse.

The election of the second species is made with traverse for the following reasons. The claims do not require the presence of binders to two antigens, or to two different antigens in the case where the claims encompass bivalent or multivalent polypeptides. Many of the examples of binding

polypeptides in the application are polypeptides that bind vWF and not another antigen on the list of second species provided by the Examiner.

Therefore, Applicant elects herewith serum albumin as a second antigen solely to comply with the species election requirement as set forth on page 3 of the paper mailed September 17, 2007. However, Applicant does not believe there is any reason that the species election requirement should be constrained to claims that require bispecific binders, i.e., to vWF and serum albumin.

Instead, Applicant wishes to have the Examiner examine vWF binders as a species, without reference to the need for a second antigen binder, i.e., a serum albumin binder. Accordingly, Applicant respectfully requests that the Examiner reconsider the species election requirement and permit the Applicant to elect as a species vWF binders.

Applicant gratefully acknowledges the Examiner's willingness to discuss the election of species by telephone on October 17, 2007, and thanks the Examiner for extending that courtesy to Applicant's representative.

Applicant's elections are made without prejudice to pursuing other inventions or species in additional applications.

The following sequences in the application correspond to the elected species, assuming Applicant's preferred election (i.e., vWF binders without reference to the need for a second antigen binder) or the species election presently made with traverse (i.e., bi- or multivalent polypeptides having vWF binders combined with serum albumin binders):

SEQ ID NO: 1 to 15, 20 to 34, 38 to 45 and 62 to 65.

Applicant notes that of the foregoing sequences, SEQ ID NO: 1-12, 20-34, 38-41 and 62-65 are solely vWF binders, and SEQ ID NO: 13-15 and 42-45 bind vWF and serum albumin.

Claims 1-12, 14, 15 and 22 presently pending in the application read on the species elected with traverse (vWF + serum albumin binders) and the preferred elected species (vWF binders without reference to the need for a second antigen binder).

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Dated: October 17, 2007

Respectfully submitted,

By



John R. Van Amsterdam

Registration No.: 40,212

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000

Attorney Docket No. A0848.70010US00

x10/17/2007x